| 2927 |
1702: Suppression of T cell activation |
1700: Impaired IL-1R1 signaling |
May 24, 2023 |
May 24, 2023 |
None
|
| 2928 |
1702: Suppression of T cell activation |
984: Impairment, T-cell dependent antibody response |
May 24, 2023 |
May 25, 2023 |
1 AOP
|
| 2027 |
1718: Suppression of IL-4 production |
1719: Impairment, TDAR |
Jan 5, 2020 |
Apr 4, 2021 |
1 AOP
|
| 3684 |
2385: Suppression of Keap1 cysteine oxidation |
1417: NFE2/Nrf2 repression |
Nov 4, 2025 |
Nov 4, 2025 |
1 AOP
|
| 2026 |
1717: Suppression of STAT5 binding to cytokine gene promoters |
1718: Suppression of IL-4 production |
Jan 5, 2020 |
Mar 30, 2021 |
1 AOP
|
| 476 |
456: Suppression, Constitutive androstane receptor, NR1l3 |
167: Activation, LXR |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 477 |
456: Suppression, Constitutive androstane receptor, NR1l3 |
228: demethylation, PPARg promoter |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 1086 |
1046: Suppression, Estrogen receptor (ER) activity |
1056: Decrease, E2 blood concentrations at hypothalamus |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 2580 |
1046: Suppression, Estrogen receptor (ER) activity |
1047: Increased, secretion of GnRH from hypothalamus |
Feb 26, 2022 |
Mar 1, 2022 |
1 AOP
|
| 1255 |
1202: Suppression, IL-2 and IL-4 production |
979: Interference, nuclear localization of NFAT |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1510 |
1202: Suppression, IL-2 and IL-4 production |
984: Impairment, T-cell dependent antibody response |
May 19, 2017 |
Jun 27, 2021 |
1 AOP
|
| 570 |
403: Suppression, Immune system |
576: Increased, Viral susceptibility |
Nov 29, 2016 |
Dec 3, 2016 |
2 AOPs
|
| 388 |
152: Suppression, Inflammatory cytokines |
168: Decreased, Lymphocytes |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 1258 |
1203: Suppression, Suppression of production of cytotoxic T-cells |
984: Impairment, T-cell dependent antibody response |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1260 |
1203: Suppression, Suppression of production of cytotoxic T-cells |
986: Impairment of TDAR |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1259 |
1204: Suppression, Suppression of T-cell dependent antibody production |
986: Impairment of TDAR |
Nov 29, 2016 |
Dec 3, 2016 |
None
|
| 1823 |
983: Suppression, Suppression of T-cell dependent antibody response (TDAR) |
986: Impairment of TDAR |
Dec 25, 2018 |
Dec 25, 2018 |
None
|
| 2362 |
1870: Sustentacular cells, decrease |
1871: olfacotry neurons, decrease |
Apr 26, 2021 |
Apr 26, 2021 |
1 AOP
|
| 2365 |
1870: Sustentacular cells, decrease |
1873: anosmia |
Apr 26, 2021 |
Apr 26, 2021 |
1 AOP
|
| 2504 |
1944: Dysfunctional synapses |
386: Neuronal network function, Decreased |
Oct 26, 2021 |
Oct 26, 2021 |
2 AOPs
|
| 2808 |
1944: Dysfunctional synapses |
341: Impairment, Learning and memory |
Dec 11, 2022 |
Dec 11, 2022 |
None
|
| 3065 |
1944: Dysfunctional synapses |
1582: Impaired axonial transport |
Oct 17, 2023 |
Oct 17, 2023 |
1 AOP
|
| 3078 |
1944: Dysfunctional synapses |
637: impaired, Learning and memory |
Oct 17, 2023 |
Oct 17, 2023 |
1 AOP
|
| 110 |
89: Synthesis, De Novo Fatty Acid (FA) |
291: Accumulation, Triglyceride |
Nov 29, 2016 |
Mar 29, 2024 |
2 AOPs
|
| 1590 |
1439: Systemic acute phase response |
1440: HDL-SAA formation |
Jun 29, 2017 |
Jun 29, 2017 |
None
|